Todd Brady
Chief Executive Officer bij ALDEYRA THERAPEUTICS, INC.
Vermogen: 5 M $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Lawrence Kenyon | M | 58 | 9 jaar | |
Matthew D'Onofrio | M | 54 | 17 jaar | |
Richard Douglas | M | 71 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 jaar |
Cam L. Garner | M | 75 | 17 jaar | |
Bruce Greenberg | M | 56 | 5 jaar | |
Neil Brewis | M | 57 | 4 jaar | |
Nancy Miller-Rich | F | 65 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 4 jaar |
Ben Bronstein | M | 74 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 14 jaar |
Tuomas R. Holmberg | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 jaar |
Jesse I. Treu | M | 76 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 9 jaar |
Gary Phillips | M | 58 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 15 jaar |
Martin Joyce | M | 70 |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 11 jaar |
Vickie Reed | F | 62 | 3 jaar | |
Malcolm R. Hill | M | 67 | 17 jaar | |
Yazan Haddadin | M | 48 | 7 jaar | |
Kenneth Widder | M | 71 | 17 jaar | |
Michael Timothy Cooke | M | 65 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 jaar |
Neal Walker | M | 54 | 11 jaar | |
Faisal Ghiath Munir Sukhtian | M | 39 | 7 jaar | |
Dean Eliott | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | 8 jaar |
James A. Gow | M | - | 4 jaar | |
Kurt Hilzinger | M | 63 | 9 jaar | |
Kelly Mizer | M | - | 3 jaar | |
Neil Walker | M | - |
Helio Vision, Inc.
Helio Vision, Inc. Pharmaceuticals: MajorHealth Technology Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA. | - |
John P. Hennessey | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 15 jaar |
Brian K. Adams | M | - |
Southeast BIO
| - |
James Sandy | M | - | 2 jaar | |
Gregory Duncan | M | 59 |
Southeast BIO
| - |
Stephen Machatha | M | 47 | 3 jaar | |
Karen Zaderej | F | 62 |
Southeast BIO
| - |
Kyp Sirinakis | F | - |
Southeast BIO
| 6 jaar |
John E. Edwards | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 19 jaar |
Geeta S. Vemuri | M | - |
Southeast BIO
| - |
Kenneth R. Tindall | M | - |
Southeast BIO
| 14 jaar |
Marilyn Carlson | M | 76 | 11 jaar | |
Garheng Kong | M | 49 |
Southeast BIO
| - |
Jan P. Turek | M | - |
Southeast BIO
| - |
Susan B. Washer | F | 63 |
Southeast BIO
| - |
Evgeny Zaytsev | M | 56 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | - |
Mike Gutch | M | 58 |
Southeast BIO
| - |
Russell Medford | M | 69 |
Southeast BIO
| - |
R. Gordon Douglas | M | 89 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | - |
Douglas Reed | M | 70 |
Southeast BIO
| 15 jaar |
William D. Kirkland | M | 60 |
Southeast BIO
| - |
Caitlin Pazzano | F | - | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
David Gonyer | M | 60 | 17 jaar | |
Darlene M. Deptula-Hicks | F | 66 | 3 jaar | |
Scott Glenn | M | 73 | 12 jaar | |
Stephen Tulipano | M | 65 | 4 jaar | |
Fred M. Haney | M | - |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 5 jaar |
Eliot Forster | M | 58 | 5 jaar | |
Jeffrey S. Halpern | M | 79 |
Dartmouth College
| 7 jaar |
Joshua Reed | M | 51 | 4 jaar | |
Albert Dyrness | M | 61 | 2 jaar | |
Joe Thomas | M | - | 2 jaar | |
Robin Hoke | F | - | 2 jaar | |
Pamela Klein | M | 63 | 3 jaar | |
Patrick Johan Hendrik Krol | M | 60 | 3 jaar | |
Edward Benz | M | 78 | 4 jaar | |
Geoff Race | M | 63 | 4 jaar | |
Chris P. Fuller | M | - |
Dartmouth College
| 7 jaar |
Nessan Bermingham | M | 51 | 3 jaar | |
C. Boyd Clarke | M | 74 |
NovaDigm Therapeutics, Inc.
NovaDigm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NovaDigm Therapeutics, Inc. developes innovative immunotherapeutics and preventative vaccines. It protect patients from fungal and bacterial infections, which can be recurrent, drug-resistant and in some cases, life-threatening. The firm NDV-3A, is the first vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by both fungal and bacterial pathogens. NDV-3A is in Phase 2 clinical development for recurrent vulvovaginal candidiasis (RVVC) with follow-on indications planned for Candida, a fungal pathogen, and Staphylococcus aureus, including MRSA. The company was founded by Toumas R. Holmberg, Michael R. Yeaman, Frederick M.Haneyand John E. Eswards Jr. in 2005 and is headquartered in Grand Forks ND. | 5 jaar |
Ann Rhoads | F | 58 | 8 jaar | |
David Arkowitz | M | 62 | 3 jaar | |
John Parker | M | - |
Dartmouth College
| 4 jaar |
Carter Strickland | M | - |
Dartmouth College
| 4 jaar |
Richie Graham | - | - |
Dartmouth College
| - |
Bryan Roberts | M | 57 |
Dartmouth College
| 4 jaar |
James Meneely | M | - |
Dartmouth College
| 4 jaar |
Christine Vanden Beukel | F | - |
Dartmouth College
| 4 jaar |
Mike Sullivan | M | - |
Dartmouth College
| 4 jaar |
Daniel Eugene Flax | M | 50 |
Dartmouth College
| 4 jaar |
Megan Hammond | F | 55 |
Dartmouth College
| 4 jaar |
Peter Kadas | M | 62 |
Dartmouth College
| 2 jaar |
Steven Kahl | M | - |
Dartmouth College
| 4 jaar |
Catherine Muller | F | - |
Dartmouth College
| 3 jaar |
John Nagel | M | - |
Dartmouth College
| 4 jaar |
Kernan V. Oberting | M | 54 |
Dartmouth College
| 4 jaar |
Brian Schmidt | M | - |
Dartmouth College
| 4 jaar |
James Terry White | M | - |
Dartmouth College
| 4 jaar |
Diane M. Musi | F | 56 |
Dartmouth College
| 4 jaar |
Mark Mader | M | 53 |
Dartmouth College
| 4 jaar |
David Shirreffs | M | - |
Dartmouth College
| 4 jaar |
Mars Jonathan Bishop | M | - |
Dartmouth College
| 4 jaar |
Jonathan B. Harrington | M | - |
Dartmouth College
| 4 jaar |
Stephen V. McKenna | M | 55 |
Dartmouth College
| 4 jaar |
Brian J. Buenneke | M | - |
Dartmouth College
| 4 jaar |
Peter B. Evans | M | - |
Dartmouth College
| 4 jaar |
John C. Rich | M | - |
Dartmouth College
| 4 jaar |
Johan Daan Goedkoop | M | 53 |
Dartmouth College
| 5 jaar |
Dana Schmaltz | M | 57 |
Dartmouth College
| 4 jaar |
Eric A. Serotta | M | - |
Dartmouth College
| 4 jaar |
Red Barrett | M | - |
Dartmouth College
| 2 jaar |
Naval Ravikant | M | - |
Dartmouth College
| 4 jaar |
Scott Edward Dudgeon | M | - |
Dartmouth College
| 4 jaar |
Harry C. Midgley | M | - |
Dartmouth College
| 4 jaar |
Ara Lovitt | M | - |
Dartmouth College
| 4 jaar |
Thomas Fisher | M | - |
Dartmouth College
| 4 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 89 | 89.90% |
Verenigd Koninkrijk | 10 | 10.10% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Todd Brady
- Persoonlijk netwerk